Covance Epidemiologist Appointments Further Strengthen Risk Management and Periapproval Services to Biopharmaceutical Companies
Princeton, New Jersey, September 26, 2006 -
Ms. Chavers brings extensive experience in epidemiology, most recently serving as a Clinical Project Specialist with Schering-Plough where she managed clinical trials and study projects as part of Schering-Plough Research Institute-sponsored studies. During her career, Ms. Chavers has worked on multiple Phase IV observational programs spanning numerous therapeutic areas. Ms. Chavers is a registered nurse and holds a master's degree in public health from the University of Alabama-Birmingham.
Dr. Vassilev brings significant experience to Covance in the areas of epidemiologic and clinical research and observational analytic epidemiology. He holds a doctorate degree in medicine from Pavlov University in Bulgaria, a master's degree in public health from Emory University and completed a post-doctoral fellowship in health indicators at Rutgers University. Dr. Vassilev most recently served as an Epidemiologist for the New Jersey Poison Control Center where he provided epidemiologic expertise including study conceptualization and design, data collection, analysis, interpretation and dissemination. As Principal Research Associate with the Institute for Treatment and Services Research, Dr. Vassilev worked on projects in the areas of substance abuse, Hepatitis C, HIV/AIDS, and health services research, and holds appointments as Assistant Professor in the New Jersey Medical School and the School of Public Health.
About Covance Risk Management and Periapproval Program Services Risk management is the ongoing process of assessing and mitigating the impact of risk throughout a product's lifecycle - from non-clinical testing to clinical trials to post marketing surveillance. With more than 40 years of experience in drug development, Covance provides an unparalleled breadth of expertise and resources to help biopharmaceutical clients meet their risk management goals across the drug development continuum.
Covance designs and implements postapproval risk minimization programs that optimize product safety and effectiveness; addressing unanswered safety questions, meeting regulatory requirements, confirming and validating effectiveness in real-world use, better defining the safety profile and providing a cornerstone for Risk Management. Covance scientific and operations teams work with biopharmaceutical clients to determine the best solution for desired outcomes, designing unique solutions for risk management and evaluation, from design through execution, analysis and reporting.
About Covance
www.covance.com, with headquarters in Princeton, New Jersey, is one of the world's largest and most comprehensive drug development services companies with annual revenues greater than $1 billion, global operations in more than 20 countries, and more than 7,400 employees worldwide. Information on Covance's products and services, recent press releases, and SEC filings can be obtained through its website at www.covance.com
Company Name: Covance, Inc.
Address 1: 210 Carnegie Center
City: Princeton
State: NJ
Zip: 08540
Phone: 8002682623
URL: www.covance.com
Contact Name: Ron Lee
E-mail: netpr@covance.com
